TY - JOUR A1 - Pakrashy, S. A1 - Mandal, P. K. A1 - Goswami, J. N. A1 - Dey, S. K. A1 - Choudhury, S. M. A1 - Bhattacharya, Biswajit A1 - Emmerling, Franziska A1 - Alasmary, F. A. A1 - Dolai, M. T1 - Bioinformatics and Network Pharmacology of the First Crystal Structured Clerodin: Anticancer and Antioxidant Potential against Human Breast Carcinoma Cell N2 - Clerodin was isolated from the medicinal plant Clerodendrum infortunatum, and CSD search showed the first crystal structure of clerodin by a single-crystal X-ray diffraction study. We checked its binding potential with target proteins by docking and conducted network pharmacology analysis, ADMET analysis, in silico pathway analysis, normal mode analysis (NMA), and cytotoxic activity studies to evaluate clerodin as a potential anticancer agent. The cell viability studies of clerodin on the human breast carcinoma cell line (MCF-7) showed toxicity on MCF-7 cells but no toxicity toward normal human lymphocyte cells (HLCs). The anticancer mechanism of clerodin was validated by its enhanced capacity to produce intracellular reactive oxygen species (ROS) and to lower the reduced glutathione content in MCF-7 cells. KW - Anticancer KW - Clerodin PY - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:b43-567600 SN - 2470-1343 VL - 7 IS - 51 SP - 48572 EP - 48582 PB - ACS Publ. CY - Washington, DC AN - OPUS4-56760 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -